Compare LNG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNG | INSM |
|---|---|---|
| Founded | 1983 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4B | 41.2B |
| IPO Year | 1997 | 2000 |
| Metric | LNG | INSM |
|---|---|---|
| Price | $192.19 | $166.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $265.46 | $188.05 |
| AVG Volume (30 Days) | 2.2M | ★ 3.1M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 14.15 | N/A |
| EPS | ★ 17.92 | N/A |
| Revenue | ★ $18,937,000,000.00 | $447,022,000.00 |
| Revenue This Year | $30.57 | $43.10 |
| Revenue Next Year | $13.71 | $128.25 |
| P/E Ratio | $10.62 | ★ N/A |
| Revenue Growth | 21.55 | ★ 30.34 |
| 52 Week Low | $186.20 | $60.40 |
| 52 Week High | $257.65 | $212.75 |
| Indicator | LNG | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 29.60 | 29.47 |
| Support Level | $186.20 | $192.50 |
| Resistance Level | $209.49 | $205.23 |
| Average True Range (ATR) | 4.17 | 7.18 |
| MACD | -0.82 | -3.68 |
| Stochastic Oscillator | 23.89 | 9.25 |
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.